Spero Therapeutics Inc (SPRO) Stock Price, Quote & News

Company Profile

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candi...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 242 1600

Website: sperotherapeutics.com

Address:

675 Massachusetts Avenue, 14th Floor, Cambridge, United States

BxxZ Mar. 18 at 10:25 AM

$SPRO Oh come on MM's ..... U know for the starters (PM) U have to drive us back to 2,5 🤣🤣🤣

0 · Reply

Inc82 Mar. 17 at 7:54 PM

$SPRO MMs playing their game

0 · Reply

Inc82 Mar. 17 at 7:06 PM

$SPRO Never holds gains.

0 · Reply

BxxZ Mar. 17 at 6:41 PM

$SPRO $GSK Run, Forrest, run..... GSK - release the Kraken....

0 · Reply

mdboss Mar. 17 at 12:08 PM

$SPRO GSK will rake in billions for years to come with Tebipenem. A GSK buyout will obviate the need to pay out the large milestone payouts and avoid HUGE revenue leak for years to come. The economics of Tebi will soon be revealed and shock everyone including most on this thread. It's been a long haul and I believe we are getting close to the finish line. Best wishes to those who share this vision. Spero means HOPE!!!!!!!!!

0 · Reply

n44 Mar. 16 at 7:22 PM

$SPRO The stock is pinned down, can never seem to make a big move from this range. I just wonder if GlaxoSmithKline is going to buyout the rest of the shares, they don’t seem to be in a hurry.

0 · Reply

n44 Mar. 16 at 7:12 PM

$SPRO The stock just doesn’t have any volume to move it up, it’s like a bloodsucking worm.

0 · Reply

Inc82 Mar. 16 at 6:42 PM

$SPRO tight range. Is it going to explode?

1 · Reply

BxxZ Mar. 16 at 2:45 PM

$GSK $SPRO Come on Forrest, run.... run (then 50% mark up - and that's it !!!) 🤣

0 · Reply

n44 Mar. 14 at 4:55 PM

$SPRO Still no milestone payment from GSK, I am surprised, it’s getting down to the last minute. I don’t own any shares but I am still interested in the outcome.

0 · Reply

Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy

Dec 19, 2025, 8:00 AM EST - 3 months ago

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

Nov 28, 2025, 8:00 AM EST - 3 months ago

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2025, 4:05 PM EST - 4 months ago

Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update

Nov 4, 2025, 4:05 PM EST - 4 months ago

Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025

Oct 21, 2025, 2:00 AM EDT - 5 months ago

PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Oct 14, 2025, 8:00 AM EDT - 5 months ago

Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek

Aug 12, 2025, 7:32 PM EDT - 7 months ago

Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:01 PM EDT - 7 months ago

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

Aug 5, 2025, 4:05 PM EDT - 8 months ago

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

Jun 11, 2025, 3:20 PM EDT - 9 months ago

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

May 28, 2025, 11:24 AM EDT - 10 months ago

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?

GSK

May 28, 2025, 7:00 AM EDT - 10 months ago

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

GSK

May 13, 2025, 4:01 PM EDT - 11 months ago

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

May 5, 2025, 8:00 AM EDT - 11 months ago

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

Apr 28, 2025, 4:01 PM EDT - 11 months ago

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

Mar 27, 2025, 8:31 PM EDT - 1 year ago

Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

Feb 25, 2025, 10:15 AM EST - 1 year ago

UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Jan 19, 2025, 8:00 AM EST - 1 year ago

Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal

Jan 10, 2025, 7:00 AM EST - 1 year ago

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

Nov 14, 2024, 4:05 PM EST - 1 year ago

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

Oct 16, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

Oct 2, 2024, 4:30 PM EDT - 1 year ago

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

Aug 9, 2024, 10:47 AM EDT - 1 year ago

Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

May 16, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

May 15, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

May 8, 2024, 8:00 AM EDT - 2 years ago

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

May 1, 2024, 4:07 PM EDT - 2 years ago

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 23, 2024, 11:37 AM EDT - 2 years ago

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Mar 13, 2024, 5:45 PM EDT - 2 years ago

Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 4:01 PM EDT - 2 years ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

Mar 6, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

Feb 28, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

Feb 26, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference

Jan 5, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics Provides Corporate Update and 2024 Outlook

Jan 2, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Nov 13, 2023, 7:05 PM EST - 2 years ago

Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 8:05 AM EST - 2 years ago

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Nov 1, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

Sep 20, 2023, 4:05 PM EDT - 2 years ago

Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference

Sep 6, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Jul 31, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

BxxZ Mar. 18 at 10:25 AM

$SPRO Oh come on MM's ..... U know for the starters (PM) U have to drive us back to 2,5 🤣🤣🤣

0 · Reply

Inc82 Mar. 17 at 7:54 PM

$SPRO MMs playing their game

0 · Reply

Inc82 Mar. 17 at 7:06 PM

$SPRO Never holds gains.

0 · Reply

BxxZ Mar. 17 at 6:41 PM

$SPRO $GSK Run, Forrest, run..... GSK - release the Kraken....

0 · Reply

mdboss Mar. 17 at 12:08 PM

0 · Reply

n44 Mar. 16 at 7:22 PM

$SPRO The stock is pinned down, can never seem to make a big move from this range. I just wonder if GlaxoSmithKline is going to buyout the rest of the shares, they don’t seem to be in a hurry.

0 · Reply

n44 Mar. 16 at 7:12 PM

$SPRO The stock just doesn’t have any volume to move it up, it’s like a bloodsucking worm.

0 · Reply

Inc82 Mar. 16 at 6:42 PM

$SPRO tight range. Is it going to explode?

1 · Reply

BxxZ Mar. 16 at 2:45 PM

$GSK $SPRO Come on Forrest, run.... run (then 50% mark up - and that's it !!!) 🤣

0 · Reply

n44 Mar. 14 at 4:55 PM

$SPRO Still no milestone payment from GSK, I am surprised, it’s getting down to the last minute. I don’t own any shares but I am still interested in the outcome.

0 · Reply

Keep22 Mar. 13 at 10:16 AM

$SPRO GSK, you are a parent of spero. Pls take care of her.

0 · Reply

Keep22 Mar. 13 at 4:39 AM

$SPRO GSK please embrace spero

0 · Reply

BxxZ Mar. 12 at 6:03 PM

$SPRO $GSK Stop the bullshit !!! Clock is tight !!! Let it run to 3,5 & offer 50% add. !!! (I'd personally preffer run to 4 & 50% up!).... Stop playing games & make some bussiness - it's time !!! Ohh yeah - it is time !!! 🤣🤣🤣

0 · Reply

DDel Mar. 11 at 9:58 PM

$SPRO long and very

0 · Reply

Biorocksme Mar. 11 at 9:13 PM

$SPRO continues to have buyers. Is this why $ITRM is selected to go otc? Someone doesnt want orlynvah to survive in the uti space. Or buy it for pennies. Quite a turd investment

2 · Reply

Zenlama Mar. 11 at 2:59 PM

$SPRO https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-03-09-2026/card/biotech-stocks-rally-on-departure-of-polarizing-fda-official-MSjPZ3XhEXbEOrftphiC?mod=mhp

0 · Reply

rubraquercus Mar. 11 at 2:55 PM

$SPRO as usual, the street knows all, and GSK knows a lot of folks at the FDA, nothing is sacred 😊

0 · Reply

Zenlama Mar. 11 at 2:02 PM

$SPRO

0 · Reply

Biorocksme Mar. 10 at 10:49 PM

$SPRO perked up so much better than $ITRM would make a nice tie up hehehe

1 · Reply

Keep22 Mar. 10 at 10:40 PM

$SPRO GSK bless spero pls

0 · Reply

Zenlama Mar. 10 at 7:12 PM

$SPRO

0 · Reply

DDel Mar. 10 at 5:38 PM

$SPRO gsk very

0 · Reply

Market Cap	145.36M
Revenue (ttm)	47.98M
Net Income (ttm)	-68.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-142.91%
Debt to Equity Ratio	0.00

Volume	389,600
Avg Vol	309,850
Day's Range	N/A - N/A
Shares Out	56.34M
Stochastic %K	75%
Beta	1.45
Analysts	Sell
Price Target	$4.50